Table 1.
Baseline demographics and clinical characteristics in axial spondyloarthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis populations (randomized sets, observed cases) a
| axSpA (n = 325) | AS (n = 178) | nr-axSpA (n = 147) | |
|---|---|---|---|
| Demographic characteristics | |||
| Age, yr | 39.6 ± 11.9 | 41.5 ± 11.6 | 37.4 ± 11.8 |
| Sex, % male | 61.5 | 72.5 | 48.3 |
| Race, % white | 90.2 | 89.3 | 91.2 |
| Disease characteristics | |||
| Time from axSpA diagnosisb (yr), median (min–max) | 3.9 (0.0 to 37.9) | 5.5 (0.2 to 37.9) | 2.5 (0.0 to 32.2) |
| Symptom duration (yr), median (min–max) | 7.7 (0.3 to 50.9) | 9.1 (0.3 to 50.9) | 5.5 (0.3 to 41.5) |
| CRPc (mg/L), median (min–max) | 13.9 (0.1 to 174.8) | 14.3 (0.1 to 174.8) | 11.9 (0.1 to 156.2) |
| Positive for HLA-B27, n (%) | 255 (78.5) | 145 (81.5) | 110 (74.8) |
| BASDAI | 6.5 ± 1.6 | 6.4 ± 1.6 | 6.5 ± 1.5 |
| BASFI | 5.4 ± 2.2 | 5.7 ± 2.2 | 4.9 ± 2.3 |
| BASMI | 3.8 ± 1.7 | 4.4 ± 1.7 | 3.2 ± 1.5 |
| ASDAS | 3.8 ± 1.0 | 3.9 ± 0.9 | 3.7 ± 1.0 |
| Total spine paind | 7.0 ± 1.9 | 7.1 ± 1.9 | 7.0 ± 1.9 |
| Nocturnal spine paind | 6.9 ± 2.3 | 6.9 ± 2.2 | 6.9 ± 2.5 |
| Prior TNF inhibitor exposure, % | 16.0 | 20.2 | 10.9 |
| Health-related quality of life | |||
| Fatigue NRSd | 6.7 ± 1.9 | 6.6 ± 2.0 | 6.7 ± 1.8 |
| SF-36 MCSd | 40.5 ± 12.1 | 40.9 ± 12.0 | 40.0 ± 12.3 |
| SF-36 PCSd | 32.5 ± 7.5 | 32.0 ± 7.3 | 33.1 ± 7.8 |
| ASQoLd | 11.8 ± 4.3 | 11.8 ± 4.3 | 11.7 ± 4.3 |
| EQ-5D VAS | 48.3 ± 19.4 | 47.3 ± 18.5 | 49.4 ± 20.4 |
aASDAS: Ankylosing spondylitis disease activity scale; ASQoL: Ankylosing spondylitis quality of life; axSpA, Axial spondyloarthritis; BASDAI: Bath ankylosing spondylitis disease activity index; BASFI: Bath ankylosing spondylitis functional index; BASMI: Bath ankylosing spondylitis metrology index; CRP: C-reactive protein; EQ-5D: EuroQoL 5 dimensions; HLA: Human leukocyte antigen; MCS: Mental component summary; nr-axSpA, Nonradiographic axial spondyloarthritis; NRS: Numerical rating scale; PCS: Physical component summary; SF-36: Short form 36 item; TNF: Tumor necrosis factor; VAS: Visual analogue scale. bFrom the start date of the primary disease. cNormal range of CRP <8.0 mg/L. dIn full analysis set population: n = 324 axSpA, 178 AS, 146 nr-axSpA. Except where indicated otherwise, values are the mean ± SD. There were no significant differences between treatment groups at baseline.